Question 1

What is BELIMUMAB used for?

Accepted Answer

BELIMUMAB (brand name BENLYSTA) is a Other indicated for 1 INDICATIONS AND USAGE BENLYSTA is indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy.

Question 2

How does BELIMUMAB work?

Accepted Answer

BELIMUMAB works through the following mechanism: 12.1 Mechanism of Action BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. BENLYSTA does not bind B cells directly, but by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells..

Question 3

What are the most common side effects of BELIMUMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for BELIMUMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is BELIMUMAB the same as BENLYSTA?

Accepted Answer

BENLYSTA is a brand name for BELIMUMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

BELIMUMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations